News und Analysen

MannKind (NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest

Investors have piled into growth stocks, particularly those involved in artificial intelligence (AI), over the past three years, and that's driven the S&P 500 higher -- in fact, the index increased

Nvidia (NASDAQ:NVDA), which develops GPUs and AI solutions for gaming and data centers, closed Thursday at $184.89, down 5.46%. The stock fell after blockbuster Q4 results and strong guidance failed

Global spending on artificial intelligence (AI) is forecast to reach $2.5 trillion in 2026, up 44% year over year, according to the researchers at Gartner. A significant portion of that money is

A lot has changed for AbbVie (NYSE: ABBV) over the past five years. Notably, the biotech company's Humira, once its biggest growth driver and the world's best-selling drug, lost patent exclusivity

Will the healthcare sector finally rebound in 2026, after underperforming broader equities in recent years? It's hard to know for sure. But rather than avoiding the entire industry because of recent

Over the past year, shares of Centessa Pharmaceuticals (NASDAQ: CNTA) have significantly outperformed broader equities as the biotech has made tremendous progress with a promising pipeline

It's hard for many people to envision what the world looked like before Amazon (NASDAQ: AMZN). Anyone under the age of 40 takes it largely for granted that getting just about anything they would

Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Wednesday at $38.16, down 1.11%. The stock slipped as investors weighed a large Vivtex partnership while

Many pharmaceutical companies are looking to develop and market the now highly popular GLP-1 drugs, which help treat diabetes, help patients lose weight, and reduce their risk of a range of

Healthcare stocks have underperformed broader equities in recent years. But plenty of companies in the sector still look like good long-term bets.

Take Regeneron Pharmaceuticals (NASDAQ: REGN), a

The S&P 500 (SNPINDEX:^GSPC) rose 0.78% to 6,891.04, the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 1.04% to 22,863.68, and the Dow Jones Industrial Average (DJINDICES:^DJI) added 0.76% to

Many people aim to save at least $1 million for their retirement years to help supplement programs like Social Security. Whether this amount is enough or not, it's certainly much better than

It's getting hard for growth investor Cathie Wood to string together back-to-back years of market-thumping results. The Ark Invest co-founder, CEO, and ace stock picker struggled to duplicate 2020's

Pfizer (NYSE: PFE) is one of the world's largest and most respected pharmaceutical companies. That is an important backdrop for dividend investors to consider as they look at the stock's lofty 6.4%

AbbVie (NYSE: ABBV) is a large drug company with a somewhat unusual portfolio of products, spanning immunology (Skyrizi and Rinvoq) to esthetics (Botox). However, for many investors, the big draw is

With Bitcoin (CRYPTO: BTC) down 47% from its all-time high of $126,000 just a few months ago, it's perhaps no surprise that crypto investors are starting to look elsewhere for opportunities.

For

If you're looking to capitalize on the rapidly growing market for weight loss drugs, you can do so in different ways. One strategy is to invest in companies like Eli Lilly or Novo Nordisk that

Novo Nordisk (NYSE:NVO), a healthcare giant that develops and markets diabetes and obesity treatments, closed Monday at $39.63, down 16.43%. The stock fell after it announced CagriSema, its

ImmunityBio (NASDAQ:IBRX), a developer of cancer and infectious-disease immunotherapies, closed Monday at $9.83, up 12.99%. The stock moved higher after earnings highlighted 700% ANKTIVA revenue

Over the past few years, the exciting field of artificial intelligence (AI) has captured much of Wall Street's attention and headlines. And sure enough, some of the leaders in AI have produced

On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 437,000 Praxis Precision Medicines (NASDAQ:PRAX) shares, estimated at $81.38 million based on quarterly average pricing.

According to